阿德福韦

10名健康志愿者，男女各半，每日1次口服阿德福韦酯10mg，连续用药7日，进行多次给药耐受性试验。

Ten subjects were orally given 10 mg of ADV tablets once daily for 7 d for multiple-dose trial .

早期的研究已经显示，对慢性乙型肝炎e抗原阴性的患者进行48周阿德福韦治疗后，获得了临床上的改善。

Early research has shown that a48-week course of adefovir provides clinical improvements in patients with HBeAg-negative chronic hepatitis B.

RP-HPLC法测定阿德福韦酯片中阿德福韦酯含量和有关物质

RP-HPLC Determination of Adefovir Dipivoxil and Related Substances in Adefovir Dipivoxil Tablets

拉米夫定耐药的HBV再感染者阿德福韦酯治疗前后HBV多聚酶基因区序列演变的研究

Evolution of HBV polymerase gene as a result of adefovir dipivoxil treatment in liver transplant patients with lamivudine resistance

阿德福韦长期治疗HBeAg阴性的慢性乙型肝炎

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B

新的HBV表型耐药分析方法的建立及阿德福韦耐药株部分生物学特性的研究

A New Strategy for Studying the Phenotype Resistance of HBV and the Study on the Biological Characteristics of Adefovir Resistance Mutants

阿德福韦酯治疗HBeAg阴性慢性乙型肝炎疗效与HBV基因型的关系

Correlation between the efficacy of adefovir dipivoxil on HBeAg-negative patients with chronic hepatitis B and HBV genotypes

阿德福韦酯联合苦参素胶囊对慢性乙型肝炎患者HBV复制及T淋巴细胞亚群的影响

Effects of adefovir dipivoxil in combination with Marine Capsules on HBV replication and T lymphocyte subsets in patients with chronic hepatitis B

结果：阿德福韦酯原料药平均含量为99.7%，CV为0.1%。

Results : The average content of adefovir dipivoxil was 99.7 % with CV of 0.1 % .

阿德福韦酯治疗HBeAg阳性慢性乙型肝炎回顾性研究

A Retrospective Study of Adefovir Dipivoxil on Treatment in Patients with HBeAg-positive Chronic Hepatitis B

目的观察阿德福韦酯挽救治疗拉米夫定治疗后HBVDNA突破患者的疗效。

Objective To evaluate the efficacy of adefovir dipivoxil ( ADV ) on chronic hepatitis B ( CHB ) patients with HBV DNA breakthrough ( > 1 .

阿德福韦酯单用或联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎的Meta分析

A meta-analysis of adefovir dipivoxil alone or in combination with lamivudine in patients with Lamivudine-refractory chronic hepatitis B

结论：阿德福韦为治疗HBeAg阳性慢性乙型肝炎的安全有效药物。

Conclusion : Adefovir is an effective and safe medication for treating HBeAg positive chronic hepatitis B.

阿德福韦酯胶囊治疗HBeAg阳性慢性乙型肝炎患者的Ⅲ期临床研究

Phase ⅲ clinical trial of adefovir dipivoxil capsule in patients with HBeAg positive chronic hepatitis B

阿德福韦酯（贺维力）治疗HBeAg阳性慢性乙型肝炎36例临床疗效观察

The Clinical Efficacy of the Adefovir Dipivoxil in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive

我们采用Holy改良方法合成阿德福韦酯原料，研制的该品为无定形粉末，对晶型专利不构成侵权。

We use the synthesis method of Holy modified . This product is amorphous powder , on the crystal form does not constitute patent infringement .

国产阿德福韦酯用于HBeAg阳性慢性乙型肝炎初治患者疗效观察

Observation of the efficacy of homemade Adefovir Dipivoxil in the primary treatment of patients with HBeAg positive chronic Hepatitis B

目的进一步研究代丁TM（阿德福韦酯/adefovirdipivoxil/ADV）在临床上用于抗病毒、保肝、抗肝纤维化的作用。

Objective The main purpose of this paper is to further investigate the antiviral , liver-protection and anti-hepatic-fibrosis efficacy of ADV ( Adefovir dipivoxil ) in clinical treatments .

本文首次建立了测定血浆中阿德福韦浓度的液相色谱-串联质谱（LC／MS／MS）法，并应用此方法对阿德福韦地匹福酯的临床前药代动力学进行了系统的研究。

A new LC / MS / MS method for determination of adefovir in animal plasma was developed and validated and successfully used in the preclinical metabolism and pharmacokinetics study of adefovir dipivoxil .

结论阿德福韦酯联合抗乙型肝炎转移因子能在一定程度上提高治疗CHB的疗效，而其对HBVDNA的影响有待进一步的研究。

Conclusions Combined application of anti-HB transfer factor and1 Adefovir could enhance the therapeutic effect in treating CHB to certain extent , but effect on HBV DNA should be study further more .

目的研究了新型抗病毒药物阿德福韦二吡呋酯（ADV）po给药后在动物体内的吸收、分布、代谢和消除过程。

AIM To reveal the process of absorption , distribution , metabolism and elimination of the antivirus agent adefovir dipivoxil ( ADV ) by animal body .

目的：评估健康志愿者单次、多次口服阿德福韦酯片剂（ADV）的药动学。

AIM : To investigate the pharmacokinetics of adefovir dipivoxil ( ADV ) with a single and multiple-dose oral administration in Chinese healthy volunteers .

结果猕猴po或iv给药ADV后，血液中只检测到活性代谢物阿德福韦（ADF），因此用ADF的血药浓度时间曲线来估算药代动力学参数。

RESULTS ADV transformed into ADF completely in plasma after po and iv administration of ADV to monkeys , so pharmacokinetic parameters were evaluated with the concentration time curves of ADF .

目的建立测定猕猴血浆中阿德福韦（adefovir）的液相色谱质谱质谱联用法。

Aim To develop a sensitive and specific liquid chromatography tandem mass spectrometry ( LC / MS / MS ) method for the determination of adefovir in monkey plasma .

本论文主要针对开环核苷酸类化合物9-（2-膦酰甲氧乙基）腺嘌呤（PMEA）即阿德福韦及阿德福韦酯的合成工艺进行了研究。

This thesis is focus on the synthetic processes of 9 - ( 2-phosphonomethoxyethyl ) adenine ( PMEA ) and adefovir dipivoxil .

在9-[2-（二乙基膦酰甲氧基）乙基]腺嘌呤合成过程中以NaH代替叔丁醇钠为催化剂低温反应，阿德福韦精制中采用控制pH值重结晶法，代替文献中的离子交换柱层析。

NaH was replaced by sodium tert-butyl alcohol as catalyst , reacting at low temperature in the synthesis of ( 9 - ( 2-phosphonyl methoxyethyl ) ethyl ) adenine . Adjustment of pH and re-crystallize took the place of ion-exchange chromato-graphy in the synthesis of adefovir .

目的：研究阿德福韦酯治疗YMDD突变后慢性乙型肝炎患者的疗效和安全性。

Objective : To observe the efficacy and safety of adefovir dipivoxil ( ADV ) for chronic hepatitis B ( CHB ) with YMDD mutation during lamivudine ( LAM ) therapy .

目的观察阿德福韦治疗拉米夫定耐药（LAM-R）慢性乙型肝炎（慢乙肝）的疗效。

Objective It is to observe the curative effect of Adefovir ( ADV ) on chronic type B hepatitis with Lamivudine resistance ( LAM-R ) .

LC-MS/MS法研究阿德福韦酯胶囊的人体药动学

Pharmacokinetic study of adefovir dipivoxil capsules by LC-MS / MS method

阿德福韦治疗拉米夫定耐药慢性乙型肝炎的研究

Study of Adefovir on chronic type B hepatitis with Lamivudine resistance